Impact of HIV-Related Immune Impairment of Yellow Fever Vaccine Immunogenicity in People Living with HIV-ANRS 12403

The yellow fever (YF) vaccine is one of the safest and most effective vaccines currently available. Still, its administration in people living with HIV (PLWH) is limited due to safety concerns and a lack of consensus regarding decreased immunogenicity and long-lasting protection for this population....

Full description

Saved in:
Bibliographic Details
Published in:Vaccines (Basel) 2024-05, Vol.12 (6), p.578
Main Authors: Caetano, Diogo Gama, Toledo, Thais Stelzer, de Lima, Ana Carolina Souza, Giacoia-Gripp, Carmem Beatriz Wagner, de Almeida, Dalziza Victalina, de Lima, Sheila Maria Barbosa, Azevedo, Adriana de Souza, Morata, Michelle, Grinsztejn, Beatriz, Cardoso, Sandra Wagner, da Costa, Marcellus Dias, Brandão, Luciana Gomes Pedro, Bispo de Filippis, Ana Maria, Scott-Algara, Daniel, Coelho, Lara Esteves, Côrtes, Fernanda Heloise
Format: Article
Language:English
Subjects:
Analysis
B cells
CD4 antigen
CD8 antigen
Cell activation
Cells
Deregulation
Dosage and administration
Evaluation
Fever
HIV
HIV patients
HIV-1
Human immunodeficiency virus
immune activation
immune exhaustion
Immune response
Immunogenicity
Immunological memory
Inflammation
IP-10 protein
Lymphocytes
Lymphocytes B
Lymphocytes T
Memory cells
Monocytes
Neutralization
Population
Vaccines
Variables
Vector-borne diseases
Viral vaccines
Yellow fever
yellow fever vaccine
Citations: Items that this one cites
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:The yellow fever (YF) vaccine is one of the safest and most effective vaccines currently available. Still, its administration in people living with HIV (PLWH) is limited due to safety concerns and a lack of consensus regarding decreased immunogenicity and long-lasting protection for this population. The mechanisms associated with impaired YF vaccine immunogenicity in PLWH are not fully understood, but the general immune deregulation during HIV infection may play an important role. To assess if HIV infection impacts YF vaccine immunogenicity and if markers of immune deregulation could predict lower immunogenicity, we evaluated the association of YF neutralization antibody (NAb) titers with the pre-vaccination frequency of activated and exhausted T cells, levels of pro-inflammatory cytokines, and frequency of T cells, B cells, and monocyte subsets in PLWH and HIV-negative controls. We observed impaired YF vaccine immunogenicity in PLWH with lower titers of YF-NAbs 30 days after vaccination, mainly in individuals with CD4 count
ISSN:2076-393X
2076-393X
DOI:10.3390/vaccines12060578